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 ABSTRACT  Cancer onset and progression involves the accumulation of multiple oncogenic hits, 
which are thought to dominate or bypass the physiologic regulatory mechanisms in 
tissue development and homeostasis. We demonstrate in T-cell acute lymphoblastic leukemia (T-ALL) 
that, irrespective of the complex oncogenic abnormalities underlying tumor progression, experimentally 
induced, persistent T-cell receptor (TCR) signaling has antileukemic properties and enforces a molecular 
program resembling thymic negative selection, a major developmental event in normal T-cell develop-
ment. Using mouse models of T-ALL, we show that induction of TCR signaling by high-afﬁ nity self-
peptide/MHC or treatment with monoclonal antibodies to the CD3ε chain (anti-CD3) causes massive 
leukemic cell death. Importantly, anti-CD3 treatment hampered leukemogenesis in mice transplanted 
with either mouse- or patient-derived T-ALLs. These data provide a strong rationale for targeted ther-
apy based on anti-CD3 treatment of patients with TCR-expressing T-ALL and demonstrate that endog-
enous developmental checkpoint pathways are amenable to therapeutic intervention in cancer cells. 
 SIGNIFICANCE: T-ALLs are aggressive malignant lymphoid proliferations of T-cell precursors charac-
terized by high relapse rates and poor prognosis, calling for the search for novel therapeutic options. 
Here, we report that the lineage-speciﬁ c TCR/CD3 developmental checkpoint controlling cell death in 
normal T-cell progenitors remains switchable to induce massive tumor cell apoptosis in T-ALL and is 
amenable to preclinical therapeutic intervention.  Cancer Discov; 6(9); 972–85. ©2016 AACR. 
See related commentary by Lemonnier and Mak, p. 946. 
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 INTRODUCTION 
 Developmental checkpoints in stem/progenitor cells are 
critical to their determination, commitment, and differentia-
tion into distinct lineages. Cancer cells often retain expression 
of lineage-speciﬁ c checkpoint proteins, but their potential 
impact in cancer remains elusive ( 1 ). T lymphocytes mature 
in the thymus following a highly orchestrated developmental 
process that entails the successive rearrangements and expres-
sion of T-cell receptor (TCR) genes. TCRδ rearrangements ﬁ rst 
occur at the CD5 + , CD1a – , CD4/8 double-negative (DN) stage, 
followed by concurrent TCRγ and TCRβ rearrangements coin-
ciding with CD1a expression. Although productive TCRγ and 
TCRδ rearrangements will determine the assembly of a TCRγδ, 
a complete productive TCRβ gene rearrangement will ﬁ rst 
allow surface expression of a pre-TCR complex formed by the 
assembly of the TCRβ chain with a pre-Tα (pTα) invariant 
chain. Pre-TCR surface expression is a critical checkpoint for 
developing αβ T-cell precursors to expand and mature into 
CD4/CD8 double-positive (DP) cortical thymocytes and for 
the initiation of Vα–Jα rearrangements. These rearrangements 
continue until a TCRα chain is formed that can associate 
with the already formed TCRβ chain to assemble a complete 
mature TCRαβ at the cell surface ( 2, 3 ). Cell surface expression 
of the TCR is a critical developmental checkpoint in estab-
lishing MHC restriction and in shaping the immunologic 
repertoire. Low-afﬁ nity recognition of self-peptide/major his-
tocompatibility complexes (self-pMHC) presented by thymic 
epithelial cells to the TCR of CD4 + CD8 + DP cortical thymo-
cytes transduces positive selection signals and commitment to 
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either the CD4 or CD8 lineages. DP thymocytes not receiving 
these signals die by lack of stimulation, whereas those that rec-
ognize self-pMHC with high afﬁ nity undergo TCR-mediated 
apoptosis and negative selection ( 4, 5 ). 
 T-cell acute lymphoblastic leukemia (T-ALL) results from 
the leukemic transformation of thymic cell precursors and 
their arrest at speciﬁ c stages of differentiation ( 6–8 ). Despite 
recent and extensive insights into the molecular and cellular 
mechanisms responsible for T-ALL onset and progression, 
survival rates remain around 50% and 70% in adult and pediat-
ric cases, respectively, calling for the search for novel therapeu-
tic options. In T-ALL, leukemic transformation of maturing 
thymocytes is caused by a multistep pathogenesis involving 
numerous genetic abnormalities that drive normal T cells 
into uncontrolled cell growth and clonal expansion. T-ALL 
is classiﬁ ed into subgroups based upon exclusive gene rear-
rangement and/or expression of a limited set of transcription 
factors including TAL1, LMO1/2, TLX1/3, associated with 
the speciﬁ c arrest at distinct stages of T-cell differentiation 
( 8–10 ). Across these molecular subclasses, a number of other 
recurrent genetic alterations are found, including inactivation 
of the  CDKN2A tumor suppressor locus, NOTCH1 pathway 
activating mutations, and many others (reviewed in ref.  11 ). 
 In this study, we hypothesized that tissue homeostatic 
regulators may be amenable to reactivation in tumor cells 
and demonstrate that experimentally induced TCR signaling 
in T-ALL induces cell death and a molecular program similar 
to negative selection of thymic T-cell progenitors. Impor-
tantly, switching on this TCR-induced cell death program 
dominates the multiple antiapoptotic and proproliferative 
mechanisms controlled by the oncogenes and altered tumor 
suppressors of T-ALL. These data provide a strong rationale 
for targeted therapy based upon anti-CD3 treatment in TCR-
expressing T-ALL. 
 RESULTS 
 T-ALL Development Is Hampered by Antigen-
Presenting Cell-Mediated TCR Stimulation 
 To investigate the role of TCRαβ activation by a deﬁ ned 
antigen in T-ALL, we stably expressed the negatively select-
ing Marilyn TCR-HY (Vα1.1Vβ6) speciﬁ c for the HY male 
antigen (DBY) in the TCR-negative ALL-SIL T-ALL cell line. 
 In vitro coculture of ALL-SIL/TCR-HY cells with splenocytes 
pulsed with increasing doses of DBY peptide, but not the 
unrelated OVA peptide, induced leukemic cell death ( Fig. 1A 
and quantiﬁ ed in  Fig. 1B ). DBY peptide did not induce apop-
tosis of parental TCR-negative ALL-SIL cells nor of ALL-SIL/
TCR-HY cells cultured in the absence of MHC-restricted 
antigen-presenting syngeneic splenocytes ( Fig. 1A ). These data 
demonstrate that TCR activation by the cognate peptide–
MHC complex results in T-ALL cell death. To determine the 
effect of persistent TCR stimulation on T-cell leukemogenesis, 
we generated double transgenic mice (hereafter referred to as 
TEL-JAK2/TCR-HY mice) expressing the TEL–JAK2 fusion 
oncogene ( 12 ) and the Marilyn TCR-HY ( 13 ) in lymphoid 
progenitors. As compared with TEL-JAK2/TCR-HY double 
transgenic females, which developed rapid and fully penetrant 
T-ALL, the majority of TEL-JAK2/TCR-HY males either failed 
to become leukemic or developed leukemia with markedly 
delayed latency ( Fig.  2A ). Flow cytometry analysis showed 
that of seven diseased male mice analyzed, two developed 
B-cell lymphoma/leukemia whereas ﬁ ve developed T-cell leu-
kemia ( Fig. 2B ). Strikingly, in the ﬁ ve T-ALL cases, transgenic 
 Figure 1.    TCR stimulation by antigen-presenting cells induces ALL-SIL/TCR-HY cell death.  A, ALL-SIL/TCR-HY cells were cocultured for 3 days with 
irradiated female splenocytes pulsed with the indicated doses of cognate DBY peptide (top), as compared with control conditions (bottom): absence of 
DBY (no peptide), presence of a noncognate peptide (+ OVA 10 μmol/L), presence of DBY without splenocytes (+ DBY 10 μmol/L), or ALL-SIL parental cells 
stimulated with splenocytes and DBY. Apoptosis was analyzed by annexin V and propidium iodide (PI) staining. Dot plots were gated on ALL-SIL cells.
 B, graphical representation of apoptosis level in 3 independent experiments as described in  A (*** P ≤ 0.0001, 0.001 ≤ ** P < 0.0001, 0.05 < * P < 0.001 ). 
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TCR-Vβ6 cell surface expression was low or absent, and leu-
kemic cells often expressed either no TCR or an endogenous 
TCR ( Fig.  2C ), suggesting that in these mice, expression of 
TCR-HY, but not of non–HY-speciﬁ c TCR complexes, was 
counterselected during leukemogenesis. We conclude that 
self-antigen TCR stimulation suppresses thymocyte malig-
nant transformation, thus delaying leukemogenesis in male 
mice. 
 To investigate whether delayed leukemogenesis in TEL-
JAK2/TCR-HY male mice could be attributed to direct anti-
genic stimulation of TCR-expressing leukemic cells, female 
TEL-JAK2/TCR-HY CD45.1 + T-ALL cells were transplanted 
to either female (HY-negative) or male (HY-positive) syn-
geneic CD45.2 + recipient mice. As compared with female 
recipients, which rapidly developed fatal T-ALL, most recipi-
ent males failed to develop leukemia and survived longer 
( Fig. 2D ). In contrast to male mice sacriﬁ ced simultaneously, 
female recipients presented high inﬁ ltration of CD45.1 + 
leukemic cells in spleen, lymph nodes, and bone marrow 
( Fig.  2E and F , and data not shown). The resistance of 
male mice to TEL-JAK2/TCR-HY–induced leukemogenesis 
depended on HY antigen MHC presentation but not upon 
an adaptive immune response, because T-ALL developed 
efﬁ ciently following transplantation of TEL-JAK2/TCR-HY 
leukemic cells in male allogeneic immunodeﬁ cient recipient 
mice ( Fig. 2G ), but not in male syngeneic immunodeﬁ cient 
recipients ( Fig.  2H ). These results show that the TCR anti-
leukemic effect depends upon its stimulation by the cognate 
peptide–MHC complex. 
 Anti-CD3 Stimulation of ALL-SIL/TCR-HY Cells 
Induces TCR Signaling and Apoptosis 
 We next investigated whether anti-CD3 treatment could 
mimic TCR signaling to induce leukemic cell apoptosis. 
Unlike control ALL-SIL cells, TCR-HY–expressing cells 
underwent massive apoptosis when treated with anti-CD3/
 Figure 2.    TCR-HY stimulation prevents T-ALL development.  A, Kaplan–Meier survival curves for male and female TEL-JAK2/TCR-HY mice.  B, leukemic 
cell-surface immunophenotype of male TEL-JAK2/TCR-HY mice.  C, ﬂ ow cytometry analysis of TCRβ and TCR-Vβ6 surface expression on leukemic cells 
from three male and three female TEL-JAK2/TCR-HY mice that developed T-ALL.  D, Kaplan–Meier survival curves for secondary female and male recipi-
ent syngeneic mice transplanted with female TEL-JAK2/TCR-HY leukemic cells.  E, spleens from recipient female and male mice transplanted as described 
in  D but sacriﬁ ced 17 days later.  F, leukemic burden analysis of spleen (left) and bone marrow (right) of mice transplanted as in  D but sacriﬁ ced at the 
time females became terminally ill. **,  P <  0.01; ***,  P < 0.001.  G, Kaplan–Meier survival curves of Swiss Nude allogeneic mice transplanted with female 
TEL-JAK2/TCR-HY leukemic cells (ns, nonsigniﬁ cant).  H, Kaplan–Meier T-ALL–free survival curves of  Rag2 −/− syngeneic mice transplanted with female 
TEL-JAK2/TCR-HY leukemic cells. 
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anti-CD28 or anti-CD3 alone (data not shown), as revealed by 
increased levels of cell-surface Annexin V, increased cleavage 
of caspase-3 and -7, and reduced cell expansion ( Fig. 3A–D ). 
Importantly, anti-CD3/anti-CD28 treatment did not affect 
cell-cycle progression  per se ( Fig. 3E and data not shown). To 
investigate the signaling properties of the mouse TCR-HY 
complex in human leukemic ALL-SIL cells, we ﬁ rst demon-
strated that CD3 cross-linking induced TCR clustering at 
the ALL-SIL cell surface ( Fig. 3F ). Next, phosphokinase-array 
analysis of anti-CD3/anti-CD28–stimulated ALL-SIL/TCR-
HY and normal human DP thymocytes showed increased 
phosphorylation of overlapping TCR signaling components, 
including the key downstream second messengers ERK, JNK, 
and AKT ( Fig.  3G ). Anti-CD3–induced phosphorylation of 
these proteins, and not of the cytokine signaling STAT3 
protein, was conﬁ rmed by ﬂ ow cytometry ( Fig. 3H and data 
not shown). Of note, inhibition of TCR signaling by cyclo-
sporine or the MEK kinase inhibitor PD184352 impaired 
anti-CD3–induced apoptosis and expression of the CD69 
and CD25 T-cell activation markers ( Fig. 3I and J ). Together, 
these results indicate that the TCR/CD3 signaling module 
is functional in T-ALL cells, and that its activation leads to 
 Figure 3.    Anti-CD3 stimulation of ALL-SIL/TCR-HY cells induces TCR signaling and apoptosis.  A, apoptosis detection by annexin V and PI staining of 
ALL-SIL and ALL-SIL/TCR-HY cells stimulated by anti-CD3/CD28–coated beads at the indicated time points.  B, percentage of annexin V–positive ALL-
SIL or ALL-SIL/TCR-HY cells either left unstimulated or stimulated by anti-CD3/CD28–coated beads for the indicated time.  C, Western blot analysis of 
caspase-3 and caspase-7 cleavage in ALL-SIL and ALL-SIL/TCR-HY cells either left unstimulated or stimulated by anti-CD3/CD28–coated beads for 48 
and 72 hours. Actin was used as a loading control.  D, growth curve of unstimulated and anti-CD3/CD28–stimulated ALL-SIL and ALL-SIL/TCR-HY cells. 
 E, percentage of unstimulated or anti-CD3/CD28–stimulated ALL-SIL/TCR-HY cells in the S-phase of the cell cycle as measured by EdU incorporation 
and 7-AAD staining of DNA.  F, ImageStream ﬂ ow cytometry imaging of ALL-SIL/TCR-HY single cells showing the recruitment of TCR-Vβ6 to a contacting 
anti-CD3–coated bead (arrowhead; each row shows one cell in bright ﬁ eld, phycoerytrin, and DAPI ﬂ uorescence and merge of three channels, ×40).  G, heat 
map representation of the normalized ratio of intensity of indicated phosphorylated (p) proteins in Proteome Proﬁ ler Human phosphokinase array, rep-
resentative of two experiments.  H, pERK, pAKT, and pSTAT3 expression detected by ﬂ ow cytometry in nonstimulated (top line in each panel) or 30-minute 
anti-CD3/CD28–stimulated (bottom line) ALL-SIL/TCR-HY cells.  I, percentage of annexin V–positive unstimulated (left) or anti-CD3/CD28–stimulated 
(right) ALL-SIL/TCR-HY cells at day 5, in the presence of indicated signaling pathway inhibitors. *,  P < 0.05.  J, inhibitory effects of indicated drugs on 
expression of T-cell activation markers (CD25 and CD69) in anti-CD3/CD28–stimulated ALL-SIL/TCR-HY for 2 days. 
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apoptosis. Importantly, similar results were observed in pri-
mary T-ALL (Supplementary Fig. S1A–S1C). 
 Targeting CD3  In Vitro Induces Human 
Primary T-ALL Apoptosis and Mimics Thymic 
Negative Selection 
 To test whether anti-CD3 stimulation of TCR-expressing 
T-ALL diagnostic samples also induced apoptosis, primary 
human T-ALL cells (see Supplementary Table S1 for the immu-
nophenotypic and genetic features of the diagnostic samples 
used) belonging to the major molecular oncogenic T-ALL 
subclasses were treated with anti-CD3/anti-CD28. Massive 
T-ALL apoptosis and TCR signaling activation were observed 
in TCR-expressing T-ALL but not in TCR-negative cases, regard-
less of their molecular oncogenic subtype ( Fig.  4A–D ). We 
next analyzed the transcriptional proﬁ les of TCR-expressing 
ALL-SIL cells either unstimulated or after TCR stimulation 
and found in the ALL-SIL TCR-induced transcriptional pro-
ﬁ le a signiﬁ cant enrichment for the TCR-induced negative 
selection signature of normal thymic progenitors (ref.  14 ; 
 Fig. 4E and F ). This shows that T-ALL apoptosis induced by 
TCR stimulation is associated with signaling cues resembling 
those of TCR-induced negative selection in normal T-cell 
progenitors. 
 Mouse and Human T-ALL Development Is 
Hampered by TCR Stimulation with Agonistic 
Monoclonal Antibodies 
 To assess the therapeutic potential of TCR stimulation 
by anti-CD3 treatment  in vivo , we ﬁ rst inoculated female 
syngeneic mice with transgenic TEL-JAK2/TCR-HY leukemic 
cells and the following day initiated treatment with either an 
 Figure 4.    Anti-CD3 induces human primary T-ALL apoptosis  in vitro and mimics thymic negative selection.  A, apoptosis analysis of primary T-ALL cells 
(UPNT419) cocultured on OP9-DL1 cells with or without anti-CD3/CD28 stimulation for 2 or 4 days.  B, ﬂ ow cytometry analysis of the induction kinetics 
of ERK1/2 phosphorylation (right) upon anti-CD3 (OKT3) stimulation of surface TCR/CD3-positive primary T-ALL (UPNT419; left).  C, box and whisker plot 
presentation of apoptosis induction for each individual TCR/CD3-positive primary, diagnostic T-ALL cells (24 cases) as compared with apoptosis induc-
tion for each individual TCR/CD3-negative primary T-ALL cells (12 cases) after 3 days of coculture on OP9-DL1 in the presence or absence of CD3/CD28 
stimulation (**,  P < 0.0001; ns, nonsigniﬁ cant).  D, before and after plot representation of the comparison of apoptosis induction in TCR/CD3-positive 
primary, diagnostic T-ALL cells (24 cases) versus TCR/CD3-negative primary T-ALL cells (12 cases) as described in C (**,  P < 0.0001; ns, nonsigniﬁ cant). 
 E, GSEA of the negative selection gene signature ( 14 ) comparing the ALL-SIL transcriptome with or without TCR activation, showing an enrichment in the 
TCR activation transcriptome.  F, scatter plot showing upregulated and downregulated genes in response to TCR activation in ALL-SIL cells. The negative 
clonal deletion gene expression signature is detailed. 
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anti-CD3ε monoclonal antibody (mAb) known to induce 
negative selection in normal thymic progenitors ( 15 ) or an iso-
typic control antibody for 5 consecutive days. Strikingly, both 
peripheral blood leukemia and fatal disease were impaired in 
anti-CD3–treated mice, whereas all mice treated with control 
antibody rapidly succumbed to leukemia ( Fig.  5A and B ). 
Importantly, treatment with anti-CD3 mAb was also effec-
tive against TEL-JAK2 T-ALL cells expressing endogenous 
surface TCRαβ ( Fig. 5C and D ). Of note, anti-CD3 treatment 
only marginally prolonged the leukemia-free survival of mice 
infused with CD3ε −/− TEL-JAK2 T-ALL cells ( Fig.  5D ). This 
shows that the extended survival seen in anti-CD3–treated 
mice inoculated with CD3ε +/+ TEL-JAK2 T-ALL ( Fig. 5D ) crit-
ically depends upon engagement of the TCR/CD3 complex 
 Figure 5.    TCR stimulation by agonistic mAb  in vivo administration inhibits mouse T-ALL development.  A and  B, percentage of TEL-JAK2/TCR-HY 
leukemic cells in peripheral blood (PB;  A ) and Kaplan–Meier survival curves ( B ) of female mice treated daily as indicated (arrows) with hamster anti-CD3 
mAb or control IgG.  C, percentage of TEL-JAK2 leukemic cells (expressing endogenous TCR) in peripheral blood leukocytes of mice that were treated 
daily with anti-CD3 or control hamster IgG.  D, Kaplan–Meier survival curves of mice injected with either TEL-JAK2 leukemic cells (expressing endogenous 
TCR), or TEL-JAK2/CD3ε −/− leukemic cells and treated daily with anti-CD3 or control hamster IgG.  E, percentage of IK L/L leukemic cells in peripheral blood 
leukocytes deﬁ ned as FSC hi , Thy1.2 + CD25 + in control IgG or anti-CD3–treated NOD/SCID/γ c−/−  (NSG) mice at the indicated time point.  F, Kaplan–Meier 
survival curves of NSG mice injected with IK L/L leukemic cells treated with hamster anti-CD3 mAb or control IgG as indicated. 
100 100
50
0
0 50 100
Time (days)
150 200
P = 0.003
50
Anti-CD3ε (n = 4)
CD3ε (n = 4)
TEL-JAK2/TCR-HY
TEL-JAK2 TEL-JAK2 and TEL-JAK2/CD3ε−/−
TEL-JAK2/CD3ε−/−
TEL-JAK2
T-
AL
L–
fre
e 
su
rv
iva
l (%
)
TEL-JAK2/TCR-HY
T-
AL
L–
fre
e 
su
rv
iva
l (%
)
T-
AL
L–
fre
e 
su
rv
iva
l (%
)
IgG (n = 6)
Anti-CD3ε e (n = 4)
Anti-CD3ε (n = 5)
Anti-CD3ε (n = 6)
IgG (n = 5)
IgG (n = 4)
IgG (n = 5)
Anti-CD3ε (n = 6)
IgG (n = 5)
IgG (n = 6)
P = 0.0069
Anti-CD3 e (n = 4)
IgG (n = 4)
0
100 100
50
0
0 50 100 150 200
50
0
4 100
IKL/L T-ALL
50
0
0 10 20 30 40
2
0
7
Time (days) Time (days)
14
0 10 20
Time (days) Time (days)
30 40 50
0 10 20
%
 le
uk
e
m
ic
 c
el
ls
 in
 P
B
(C
D4
5.1
+
 
CD
45
.2
+
CD
8+
 
Vβ
6+
)
%
 o
f l
eu
ke
m
ic
 c
el
ls
 in
 P
B
(F
SC
hi
 
Th
y1
.2
+
, 
CD
25
+
)
%
 le
uk
e
m
ic
 c
el
ls
 in
 P
B
(C
D4
+
 
CD
8+
)
Time (days)
30
A
C
B
D
E F
Research. 
on February 8, 2019. © 2016 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Published OnlineFirst June 28, 2016; DOI: 10.1158/2159-8290.CD-15-0675 
 SEPTEMBER  2016CANCER DISCOVERY | 979 
TCR Activation Is Tumor Suppressive in T-cell Leukemia RESEARCH ARTICLE
expressed by leukemic cells. To ensure that the results were 
not restricted to this particular model of activated tyros-
ine kinase–induced T-ALL, we extended these analyses to 
 Ikzf1/Ikaros -mutant–induced T-ALL. Although  Ikaros is rarely 
found mutated in T-ALL, recent evidence points to a suppres-
sive function of  Ikaros in NOTCH-mutated T-ALL cells ( 16 ). 
Treatment with anti-CD3 mAb inhibited leukemia expansion 
in this model ( Fig. 5E ), which translated into increased sur-
vival of anti-CD3–treated mice ( Fig. 5F ). 
 Finally and most importantly, we investigated whether 
anti-CD3 treatment also displayed antileukemic activity 
against human CD3-positive T-ALL diagnostic cases. Mice 
were xenotransplanted with cells from seven distinct human 
T-ALL cases, ﬁ ve of them expressing a TCR at the cell surface, 
one (UPNT374) showing a heterogeneous TCR expression 
pattern, and the last one (UPNT525) being negative for TCR 
cell-surface expression. Mice were treated 24 hours later 
with either anti-CD3 mAb or an isotypic control antibody. 
For all TCR + T-ALL samples, anti-CD3 treatment showed 
strong antileukemic effects, as shown by delayed dissemina-
tion in blood, bone marrow, and other organs ( Fig. 6A–D ), an 
effect that translated into enhanced recipient mouse survival 
( Fig.  6E and Supplementary Fig.  S2). In contrast, leukemic 
mice inoculated with TCR-negative T-ALL cells were insen-
sitive to anti-CD3 treatment ( Fig.  6B and Supplementary 
Fig.  S2). Mice infused with UPNT374 cells only transiently 
responded to anti-CD3 ( Fig. 6B and Supplementary Fig. S2). 
Interestingly, leukemic cells recovered from anti-CD3–treated 
 Figure 6.    TCR stimulation by  in vivo administration of agonistic mAb in a preventive setting inhibits human T-ALL development.  A, ﬂ ow cytometry 
monitoring of leukemia burden in peripheral blood (PB) from NSG mice injected with human T-ALL M106 and UPNT419 and treated daily with either 
OKT3 or an isotype control IgG (arrows).  B, tumor burden in peripheral blood of NSG mice injected with human primary T-ALL cells either mCD3/TCR posi-
tive: M106 ( n = 6 in each group), UPNT419 ( n = 5 in each group), UPNT420 ( n = 5 in each group), M149 ( n = 6 in each group) UPNT610 ( n = 5 in each group), 
or mCD3/TCR negative: UPNT525 ( n = 5 in each group), or heterogeneous for CD3/TCR expression: UPNT374 ( n = 5 in each group). Mice were treated 
with either control IgG or OKT3 in a preventive setting. Data show tumor burden in peripheral blood analyzed at the time when IgG-treated mice were 
moribund and sacriﬁ ced, except for UPTN610. For all TCR + leukemias, the  P value was <0.0001.  C, leukemia burden in spleen (top) and bone marrow 
(BM; bottom) of control and OKT3-treated mice that were sacriﬁ ced when IgG-treated control mice were leukemic (day 31 of A). *,  P = 0.0409 (spleen); 
*,  P = 0.011 (BM).  D, H&E-stained bone marrow and liver sections of mice analyzed in  B . The arrow indicates inﬁ ltrating cells in liver perivascular spaces 
and sinusoids.  E, Kaplan–Meier survival curves of NSG mice transplanted with M106 and UPNT419 human T-ALL cells analyzed as in  A .  F, ﬂ ow cytometry 
analysis of cell surface TCR in leukemic BM cells of NSG mice xenografted with T-ALL UPNT374 treated with either control IgG (black/gray tracings) or 
OKT3 (red to pink tracings) at the time of sacriﬁ ce. Green tracing shows staining with the control isotypic antibody. 
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mice showed low or absence of TCR cell-surface expression in 
contrast to the leukemic cells that expanded in control IgG-
treated mice ( Fig.  6F ). This conﬁ rms the speciﬁ c depletion 
of TCR-positive leukemic cells in response to TCR activa-
tion. We next investigated whether anti-CD3 treatment could 
also result in antileukemic effects in a curative setting. First, 
NOD/SCID/IL2Rgc −/−  (NSG) mice were inoculated with the 
luciferase-expressing human ALL-SIL/TCR-HY cells and then 
treated with either a control or an anti-CD3 mAb when mice 
presented leukemia engraftment in bone marrow (day 22 
after inoculation, data not shown). Comparison of the two 
groups by live imaging showed a speciﬁ c antileukemic effect 
of anti-CD3 treatment ( Fig.  7A , top, and  7B ). To investi-
gate whether anti-CD3 antileukemic effects were dependent 
upon TCR signaling, we sought to silence the expression of 
LAT, a critical adaptor in TCR signaling in thymocytes and 
mature T cells ( 17 ). shRNAs to LAT resulted in LAT expres-
sion knockdown in ALL-SIL/TCR-HY cells (Supplementary 
Fig.  S3A) and had no effect on TCR cell-surface expression 
(Supplementary Fig.  S3B). LAT knockdown impaired anti-
CD3–induced  in vitro apoptosis (Supplementary Fig.  S3C) 
and antileukemic effects  in vivo ( Fig.  7A and B and Supple-
mentary Fig.  S3D and S3E). As expected, LAT expression 
knockdown was maintained in leukemic cells retrieved from 
control and anti-CD3 mAb-treated mice (Supplementary 
Fig.  S3F). In a second experiment, mice xenotransplanted 
with cells from T-ALL UPNT419 were treated with the 
anti-CD3 or control mAb when leukemic cell burden reached 
10% to 20% of bone marrow cells. Leukemia expansion was 
strongly delayed in anti-CD3–treated mice, in contrast to the 
rapid expansion of leukemic cells in control mice ( Fig.  7C ). 
Despite the reemergence of peripheral blood leukemic cells 
upon cessation of treatment, survival of anti-CD3–treated 
mice was signiﬁ cantly prolonged ( Fig.  7D ). Thus, antibody-
mediated TCR engagement results in striking antileukemic 
effects in xenotransplanted human T-ALLs in both preventive 
and curative settings. 
 DISCUSSION 
 Current T-ALL therapies involve complex, often toxic 
chemotherapeutic regimens. Although T-ALL outcome has 
improved with current therapies, survival rates remain only 
around 50% and 70% at 5 years in adult and pediatric T-ALL, 
respectively ( 18, 19 ). The genetic bases of T-ALL progres-
sion and maintenance are well characterized but have not 
translated so far into targeted therapies ( 11 ). There is thus 
unmet need for new treatments to offer therapeutic options 
for refractory disease and to prevent relapse. We previously 
observed that expression of a TCR transgene in a TCR-nega-
tive T-ALL cell line can induce cell death, provided these cells 
are subjected to differentiation-inducing cues ( 20 ). We report 
here that chronic/strong TCR signaling causes massive apop-
tosis of primary T-ALLs that express an endogenous TCR 
 Figure 7.    TCR stimulation by administration of agonistic mAb in a curative setting inhibits human T-ALL development.  A, tumor burden in NSG 
mice xenotransplanted with human ALL-SIL/TCR-HY luciferase-expressing cells transduced with either the LKO control vector (top) or the LKO vector 
encoding  LAT shRNA #1 (bottom). Once leukemic, mice daily received either IgG control or anti-CD3 mAb (OKT3), and bioluminescence at day 48 after 
xenotransplantation is shown (luminescence color scale: minimum = 8.00 × 10 4 to maximum = 2.00 × 10 6 radiance).  B, bioluminescence quantiﬁ cation over 
time of the experiment shown in  A .  C, tumor burden in peripheral blood of NSG mice xenotransplanted with human T-ALL cells (UPNT419) and treated 
with either control IgG or OKT3 when mice were leukemic.  D, Kaplan–Meier survival curves of NSG mice transplanted with UPNT419 analyzed in  C . 
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and shows potent tumor-suppressive function  in vivo . These 
ﬁ ndings call for the incorporation of TCR-directed therapies 
in current treatment regimens of CD3-expressing T-ALL. 
Muromonab-CD3 (OKT3) was approved by the FDA in 1985 
for therapy of acute, glucocorticoid-resistant rejection of allo-
geneic renal, heart, and liver transplants ( 21 ) and was in fact 
the ﬁ rst mAb introduced in the clinic. Since then, a number 
of other monoclonal antibodies to CD3 were developed ( 22 ) 
that may prove superior to OKT3 in T-ALL treatment. Of 
note, encouraging response to OKT3 therapy was reported in 
an adult patient with an aggressive and chemotherapy-resist-
ant T-ALL, but the basis of this response was not studied ( 23 ). 
 A major drawback of current chemotherapeutic regimens 
in T-ALL is the frequent resistance to treatment and relapse. 
Leukemia initiating cells (LIC) from residual disease are 
thought to be responsible for relapsing cases ( 24, 25 ). In 
addition, resistance of T-ALL to chemotherapy is in part 
linked to the recurrent genetic abnormalities selected dur-
ing disease progression, e.g., inactivation of the  PTEN tumor 
suppressor gene and the resulting activation of PI3K/AKT 
signaling ( 26, 27 ). Whether administration of anti-CD3 
therapy during the remission phase or its association with 
conventional chemotherapy regimens could target LICs 
and/or bypass molecular mechanisms of primitive resist-
ance represent promising directions to be explored in future 
prospective studies. 
 T cells mature in the thymus following a highly orches-
trated process controlled by both cell-intrinsic (e.g., transcrip-
tion factors) and cell-extrinsic (e.g., stroma-derived cytokines/
chemokines) molecular cues ( 28, 29 ). Cell-surface TCRαβ 
expression in DP thymocytes allows recognition of speciﬁ c 
self-MHC/peptide to transduce a positive selection signal and 
maturation into single-positive thymocytes. DP thymocytes 
not receiving this signal die through lack of stimulation, 
whereas those whose TCR binds too strongly to self-MHC/
peptide undergo activation-induced apoptosis and negative 
selection ( 5, 30 ). In both situations, TCR binding to self-
pMHC is the triggering event, but how TCR engagement 
leads to such divergent outcomes (survival and prolifera-
tion versus death) remains unclear ( 31 ). Remarkably, these 
two contrasting processes are driven by a TCR signaling 
machinery of qualitatively similar composition ( 30 ). Available 
evidence indicates that the difference lies in the molecular 
interpretation of signals of different strength, which may 
rely on compartmentalization of key signaling players ( 32 ), 
and in the induction of divergent, complex transcriptional 
responses ( 14, 33 ). Indeed, it has been shown that a small 
increase in ligand afﬁ nity for the TCR leads to a marked 
change in the subcellular localization (plasma membrane 
for negative selecting ligands vs. Golgi complex for positively 
selecting ones) of essential adaptors of the RAS signaling 
pathway. This compartmentalization induces the conversion 
of a small change in analogue input (afﬁ nity for ligand) into 
a digital output (positive vs. negative selection; refs.  32, 34 ). 
Our results show that the antileukemic activity of anti-CD3 
mAb depends upon TCR signaling cues, as it was impaired 
upon LAT silencing in T-ALL cells. This also suggests that, 
in the present experimental setting, antibody dependent cell-
mediated cytotoxicity (ADCC)–like responses of the host 
play a minor role in anti-CD3 antileukemic properties. It 
is likely that in patients with T-ALL eligible for anti-CD3 
therapy (about half of pediatric and 30% of adult cases), 
ADCC-like responses will play a more important role than in 
immunosuppressed mice and will add therapeutic value to 
the intrinsic antileukemic effects of anti-CD3. In addition, 
in a clinical context, TCR downregulation and/or selection 
of a TCR-negative subclone, as observed here in a xenotrans-
planted T-ALL under pressure of anti-CD3 treatment, could 
constitute a potential escape mechanism to treatment. These 
ﬁ ndings need to be explored in clinical trials. More extensive 
studies on the composition and function of TCR-induced 
signalosomes formed in T-ALL stimulated by anti-CD3 and 
the identiﬁ cation of critical components in T-ALL of the 
transcriptomic signature akin to that of thymic negative 
selection ( 14, 35, 36 ) should provide information on the 
molecular pathways involved in anti-CD3–induced apoptosis 
in leukemic cells. These pathways could in turn constitute 
new pharmaceutical targets to treat T-ALL. 
 Although signaling from the B-cell receptor (BCR) and 
pre-BCR was shown to promote B-cell malignancies ( 37, 38 ), 
the role of TCR signaling in T-ALL has thus far remained 
controversial. Studies in T-ALL mouse models indicated a pro-
oncogenic role for TCR signaling ( 39–42 ). However, these data 
were based on transgenic TCR systems, which do not reﬂ ect the 
expression levels and receptor diversity found among patients 
with T-ALL where TCR expression is heterogeneous or absent 
( 6 ). Moreover, gene inactivation studies in other mouse T-cell 
leukemia models have shown that TCR expression is not essen-
tial for T-ALL development ( 43, 44 ). The current work demon-
strates that anti-CD3–mediated activation of endogenous TCR 
in human T-ALL has an antileukemic function. T-ALL often 
arises from immature T-cell precursors before the stage of neg-
ative selection ( 6, 42 ). Consequently, contingent expression of a 
non–negatively selecting TCR will render T-ALL cells sensitive 
to TCR-activating apoptotic signals that mimic negative selec-
tion, as demonstrated here by anti-CD3 treatment  in vitro and 
 in vivo . However, during T-ALL development, it is possible that 
selective events enable cells to escape post-malignancy negative 
selection, such as loss of TCR surface expression, as found in 
a subset of  patients with T-ALL ( 6 ) and as demonstrated here 
in TEL-JAK2/TCR-HY double transgenic male mice. Such leu-
kemias could be amenable to other therapies targeting down-
stream TCR signaling effectors. 
 The dual role of developmental molecular pathways in 
organogenesis and tumorigenesis is increasingly recognized, 
the modulation of which may provide potential therapeutic 
opportunities ( 1 ). In line with this, experimental restoration 
of cell-surface expression of Igα and Igβ in Ph + B-ALL was 
also shown to result in cell death ( 45 ). In our study, we found 
that reactivation in TCR-positive T-ALL blasts of the lineage-
speciﬁ c checkpoint control normally set by TCR signaling 
during T-cell development displays antitumoral functions. 
Importantly, despite the multiple and complex oncogenic 
mechanisms driving T-ALL, which include antiapoptotic ( 46 ) 
and proproliferative ( 47 ) signaling cues, this TCR-depend-
ent checkpoint remains switchable to induce massive tumor 
cell apoptosis. Thus, reactivation of similar lineage-speciﬁ c 
developmental checkpoints in malignancies originating from 
other lineages and tissues could provide a novel class of thera-
peutic targets in cancer. 
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 METHODS 
 Mice 
 TEL-JAK2 mice were bred with Marilyn transgenic, RAG2-deﬁ cient 
or CD3ε-deﬁ cient mice (all maintained on the C57BL/6 background), 
as described previously ( 43 ). Swiss Nude and NSG mice were pur-
chased from Charles River Laboratories. IK L/L mice, carrying two 
alleles of the hypomorphic IK L allele ( 48 ), were a generous gift from 
Dr. P. Kastner (IGBMC, Strasbourg, France). Mice were maintained 
under speciﬁ c pathogen-free conditions in the animal facilities 
of the Institut Curie (Orsay, France) or University of Algarve 
(Faro, Portugal). NSG mice were maintained under constant anti-
biotic treatment (Baytril 0.01% in drinking water). All experimental 
procedures were performed in strict accordance with the recom-
mendations of the European Commission (Directive 2010/63/UE), 
French National Committee (87/848), and Portuguese authorities 
(Decreto-Lei nº113/2013) for the care and use of laboratory ani-
mals. Mice were euthanized when terminally ill, as evidenced by 
either severe dyspnea or weakness caused by leukemic dissemina-
tion in the thymus or vital organs (bone marrow, lung, and liver), 
respectively. For mouse leukemia transplantation assays, 0.5–2 
× 10 6 leukemic cells collected from diseased female TEL-JAK2/
TCR-HY, TEL-JAK2, TEL-JAK2/CD3ε −/− ,  or IK L/L mice were intra-
venously injected in the tail vein of recipient 8-to-12-week-old 
C57BL/6 or NSG mice (for the IK L/L tumor) of the indicated gender 
and genotype and regularly monitored through peripheral blood 
detection of leukemic cells (CD45.1 + CD45.2 + TCR-Vβ6 + TEL-JAK2/
TCR-HY cells or CD4 + CD8 + TEL-JAK2 cells). Anti-CD3ε (145-
2C11) mAb or control ChromPure Syrian Hamster IgG (Jackson 
Immunoresearch) was diluted in sterile PBS and intravenously 
administered on a regimen of 20 μg/mouse/day for 5 consecutive 
days for the TEL-JAK2 tumors and on a regimen of 50 μg/mouse/
day for 2 periods of 5 consecutive days separated by a 2-day pause 
for the IK L/L leukemia. For human leukemia xenotransplantation 
assays, 1 × 10 6 fresh leukemic cells obtained from primary NSG 
mice engrafted with patient-derived cells from T-ALL cases M106, 
UPNT419, UPNT420, M149, UPNT610, UPNT374, and UPNT525 
were intravenously injected in 2-month-old NSG mice. These mice 
were injected intravenously with either anti-CD3ε OKT3 mAb 
(BioXCell; 40 μg/mouse/day treatment for 2 rounds of 5 con-
secutive days separated by a 2-day interval) or the isotype-matched 
(IgG2a) C1.18.4 mAb (BioXCell), both diluted in PBS. In the cura-
tive setting, mice were treated as above when leukemic cells reached 
1% to 4% of blood nucleated cells. Mice were monitored weekly by 
ﬂ ow cytometry for leukemic load (FSC hi , hCD7 + , hCD45 + cells) 
in peripheral blood. Statistical analyses and survival curves were 
calculated using Prism 5 (GraphPad). Kaplan–Meier survival curves 
were compared using the log-rank test. Histologic analyses were 
performed on parafﬁ n-embedded sections as detailed in the Sup-
plementary Methods. 
 T-ALL Patient Samples and Cell Lines 
 Immunophenotypic and oncogenic features of patients with 
T-ALL were identiﬁ ed as described ( 6, 27, 49, 50 ) and detailed in 
Supplementary Table 1 . Fresh or thawed primary T-ALL samples 
(peripheral blood or bone marrow) obtained at diagnosis from adult 
and pediatric patients were used, as well as T-ALL cells xenografted 
in NSG mice. T-ALLs were all included within the GRAALL-2005 
study, and informed consent was obtained from all patients at trial 
entry (trial registration ID: NCT00327678). Studies were conducted 
in accordance with the Declaration of Helsinki and approved by 
local and multicenter research ethical committees. All samples used 
contained ≥80% blasts. CD4 + CD8 + (DP) human thymocytes were 
obtained and processed as described in the Supplementary Methods. 
The ALL-SIL cell line (DSMZ; ACC511) was grown  in vitro and trans-
duced as described in the Supplementary Methods. The ALL-SIL 
parental line and all derivatives were authenticated by short tandem 
repeat DNA proﬁ ling on June 10, 2016. 
 In Vitro TCR Stimulation by Antigen-Presenting Cells 
 Splenocytes were obtained from C57BL/6 female mice, subse-
quently irradiated (2000 rad) and preincubated with antigenic 
peptides at 37°C for 1 hour (peptide pulsing). Peptides used were 
DBY (NAGFNSNRANSSRSS), the male antigen epitope speciﬁ -
cally recognized by Marilyn transgenic TCR-HY, at 10, 1, 0.1, 0.01, 
0.001, and 0.0001 μmol/L, and OVA (ISQAVHAAHAEINEAGR), a 
nonspeciﬁ c peptide, at 10 μmol/L. Splenocytes were then plated out 
in 48-well plates, without removal of peptides. ALL-SIL/TCR-HY 
cells were added to the coculture system at a 1:100 ratio. Control 
conditions were performed in parallel with non-pulsed splenocytes, 
DBY without splenocytes, and ALL-SIL without transgenic TCR 
cocultured on DBY-pulsed splenocytes. Apoptosis was analyzed by 
ﬂ ow cytometry at day 3 of culture, as described in the Supplemen-
tary Methods . 
 Flow Cytometry Analysis of Leukemic Cells 
 Cell suspensions prepared from mouse lymphoid organs, bone 
marrow, or blood were stained with ﬂ uorochrome-labeled antibod-
ies and analyzed on a FACSCalibur cytometer (BD Biosciences), as 
described ( 43 ). The list of antibodies used is described in the Sup-
plementary Methods. Data were analyzed using Diva, CellQuest (BD 
Biosciences) and FlowJo (TreeStar) softwares. 
 Anti-CD3/CD28 Cell Stimulation 
 Short-term stimulation was performed on cells cultured in 
serum-free medium for at least 15 minutes at 37°C prior to stimu-
lation. Murine anti-hCD3 mAb (OKT3, Biolegend; 20 μg/mL) was 
added to the cell culture on ice for 10 minutes and mAbs were 
then cross-linked by the addition of goat–anti-mouse antibody 
to a ﬁ nal concentration of 50 μg/mL for 15 minutes. Stimula-
tion (0–10 minutes) was triggered by warming cells at 37°C and 
terminated either by cooling cells in cold PBS or ﬁ xing cells for 
phosphokinase array and intracellular phosphoprotein (Phosﬂ ow) 
assays, respectively. For prolonged stimulation, a bead-based assay 
was used in which cell lines were cultured in 96- or 24-well plates 
and exposed to 4.5-μm diameter superparamagnetic beads cova-
lently coupled to anti-CD3 and anti-CD28 antibodies (Dynabeads 
Human T-Activator CD3/CD28, Invitrogen; duration of stimula-
tion from 1 to 12 days). Prolonged stimulation of primary T-ALL 
cells was performed in a coculture assay with conﬂ uent OP9-DL1 
in an α-MEM media supplemented with 20% FBS (Hyclone; Ther-
moFisherScientiﬁ c), 50 μg/mL streptomycin, and 50 IU penicillin 
and recombinant human cytokines hFLT3L (5 ng/mL), hIL7 (2 ng/
mL), and hSCF (10 ng/mL; Miltenyi). Similarly, CD3/CD28-coated 
beads were added to the coculture assay following the manufac-
turer’s instructions. 
 Intracellular Flow Cytometry with 
Phosphorylation-Speciﬁ c Antibodies 
 Stimulation of cells was terminated by ﬁ xation with prewarmed 
formaldehyde (Cytoﬁ x Buffer; BD Biosciences) at 37°C for 10 min-
utes. After cooling on ice for 1 minute, cells were pelleted at 4°C 
and permeabilized in 1 mL of ice-cold methanol (Perm Buffer III; 
BD Biosciences). After 30 minutes, cells were washed 3 times with 
3 mL of PBS and resuspended in 50 μL PBS for intracellular stain-
ing with phospho-ERK1/2-Alexa647 (pT202/pY204), phospho-
STAT3-Alexa488 (pY705; BD Biosciences) or phospho-AKT-Alexa647 
(pS473; Cell Signaling Technology) and incubated for 20 minutes at 
room temperature. After washing, cells were resuspended in PBS for 
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ﬂ ow cytometric analysis on FACSCanto II (BD). Data were processed 
using Cytobank software. 
 Western Blot Analyses 
 Sample processing and analysis are described in Supplementary 
Methods. 
 Flow Cytometry Analysis of TCR Clustering 
 ALL-SIL/TCR-HY cells were stained with TCR Vβ6-PE mAb (BD 
Biosciences) for 30 minutes at 4°C and DAPI for 5 minutes at room 
temperature prior to stimulation and split into two samples; one 
sample remained unstimulated whereas the other one was stimulated 
by styrene beads (Polyscience) precoated with human anti-CD3ε 
antibody (OKT3; Biolegend) for 10 minutes at 37°C. Cells were ﬁ xed 
with 1% formaldehyde. Staining was analyzed using ImageStream X 
mkII (Amnis Merck-Millipore). Data analysis was performed using 
the IDEAS image analysis software (Amnis). 
 Phosphokinase Antibody Array Analysis and 
Pharmacologic Inhibition 
 ALL-SIL, ALL-SIL/TCR-HY cells, human DP thymocytes, and 
CD3-negative (UPNT525) and CD3-positive (M149) primary T-ALLs 
either were left unstimulated or were stimulated with CD3/CD28 
mAbs for 5 minutes. Each stimulated condition was performed in 
replicate. Cell lysates and Proteome Proﬁ ler Human phosphokinase 
array (R&D Systems) were performed according to the manufac-
turer’s protocol. Chemiluminescence was detected by ChemiDoc 
XRS+ (Bio-Rad). The average signal (pixel density) of duplicate 
spots representing each phosphorylated kinase protein was normal-
ized with the average signal of reference positive duplicate spots 
of each membrane using Image Lab software (Bio-Rad). Signal 
ratios for selected phosphoproteins were displayed in a heat map 
using Treeview software. Cyclosporine A (Novartis) and PD184352 
(Selleckchem) were used at 1 μmol/L. Effects were determined by 
analysis of apoptosis (Annexin V/PI assay) and expression of CD25 
and CD69 activation markers. 
 Microarray Gene Expression Proﬁ ling 
 RNA extraction was performed for the following cells: ALL-SIL/
TCRαβ-GFP cocultured on OP9-DL1 and ALL-SIL/TCRαβ-GFP 
without coculture. These samples were obtained as previously 
described ( 14 ) in duplicate, and RNA extraction was performed at 
an early time point before apoptosis onset (48 hours of coculture 
for ALL-SIL/TCRαβ-GFP). RNA hybridization was performed on 
Affymetrix U133 plus 2.0 microarrays. The statistical data analysis 
was performed with R version 2.9.0 using the “Affy” package from 
Bioconductor. The probe intensities were log 2 transformed and 
normalized using Robust Multiarray Average. Identiﬁ cation of dif-
ferentially expressed genes was performed by Signiﬁ cance Analysis 
of Microarrays, using 500 permutations and a false discovery–rate 
threshold of 5%. Gene Set Enrichment Analysis (GSEA) was per-
formed using the negative selection signature described by Baldwin 
and colleagues ( 14 ) as gene set. GSEA was run using signal-to-noise 
for the ranking gene metric and 1,000 permutations. All microar-
ray data have been submitted to the Gene Expression Omnibus 
database under accession number GSE65496. 
 Luciferase Xenograft Studies 
 A total of 1 × 10 6 control pLKO or pLKO-sh LAT GFP-Lucif-
erase sorted ALL-SIL/TCR-HY cells were intravenously injected into 
2-month-old NSG mice ( n = 10). Isoﬂ uorane-anesthesized mice were 
intraperitoneally injected with 2.5 mg of D-luciferin (CALIPER Life 
Sciences) and monitored on a weekly basis to detect luciferase activ-
ity using an IVIS Spectrum (Perkin-Elmer). When leukemic cells were 
detected (22 days after injection), mice were treated with either OKT3 
or control mAb as described above. 
 Disclosure of Potential Conﬂ icts of Interest 
 No potential conﬂ icts of interest were disclosed . 
 Authors’ Contributions 
 Conception and design: A. Trinquand, N.R. dos Santos, C. Tran Quang, 
N. Ifrah, E. Macintyre, J. Ghysdael, V. Asnaﬁ  
 Development of methodology: A. Trinquand, C. Tran Quang, 
F. Rocchetti, B. Zaniboni, F.-L. Cosset, E. Verhoeyen, F. Pﬂ umio, N. Ifrah, 
D.-A. Gross, J. Ghysdael, V. Asnaﬁ  
 Acquisition of data (provided animals, acquired and managed 
patients, provided facilities, etc.): A. Trinquand, N.R. dos Santos, 
C. Tran Quang, C. Da Costa de Jesus, M. Tesio, M. Dussiot, F. Pﬂ umio, 
H. Dombret, J. Ghysdael, V. Asnaﬁ  
 Analysis and interpretation of data (e.g., statistical analysis, bio-
statistics, computational analysis): A. Trinquand, N.R. dos Santos, 
C. Tran Quang, M. Belhocine, C. Da Costa de Jesus, L. Lhermitte, 
M. Dussiot, N. Ifrah, S. Spicuglia, O. Hermine, J. Ghysdael, V. Asnaﬁ  
 Writing, review, and/or revision of the manuscript: A. Trin-
quand, N.R. dos Santos, C. Tran Quang, M. Belhocine, E. Verhoeyen, 
N. Ifrah, H. Dombret, L. Chatenoud, O. Hermine, E. Macintyre, 
J. Ghysdael, V. Asnaﬁ  
 Administrative, technical, or material support (i.e., reporting or 
organizing data, constructing databases): A. Trinquand, E. Verhoeyen, 
N. Ifrah, L. Chatenoud, E. Macintyre, J. Ghysdael 
 Study supervision: A. Trinquand, C. Tran Quang, N. Ifrah, E. Macin-
tyre, J. Ghysdael, V. Asnaﬁ  
 Acknowledgments 
 We thank E. Belloir and C. Alberti for assistance with mouse hus-
bandry, Anne Reynaud for help with blood analyses, and Charlene 
Lasgi from the ﬂ ow-cytometry platform of the Institut Curie. 
 Grant Support 
 A. Trinquand was supported by a grant from INCa (Institut 
National du Cancer: “Soutien à la Recherche Translationnelle 2012”). 
N.R. dos Santos was supported by an FCT Investigator contract 
(Fundação para a Ciência e Tecnologia) and institutional support 
(UID/BIM/04773/2013 CBMR). This work was supported in the 
Necker team by grants from the Institut National du Cancer (INCa) 
PLBIO13-218 and PLBIO15-094, “La Ligue Contre le Cancer” and 
the SFCE (Société Française des Cancers de l’Enfant), la Fédération 
Enfants et Santé, les associations l’Etoile de Martin, Hubert Gouin 
“Enfance et Cancer,” Les Bagouz’s à Manon, Capucine, AREMIG et 
Thibault Briet, and la Fondation EDF; and in the Institut Curie team 
by funds from Institut Curie, CNRS, INSERM, INCa (PLBIO15-094), 
and Ligue Contre le Cancer (Comité de l’Essonne). 
 The costs of publication of this article were defrayed in part by 
the payment of page charges. This article must therefore be hereby 
marked  advertisement in accordance with 18 U.S.C. Section 1734 
solely to indicate this fact. 
 Received  June  4 ,  2015 ;  revised  June  24 ,  2016 ;  accepted  June  24 , 
 2016 ; published OnlineFirst June 28, 2016. 
 REFERENCES 
  1.  Garraway  LA ,  Sellers  WR .  Lineage dependency and lineage-survival 
oncogenes in human cancer .  Nat Rev Cancer  2006 ; 6 : 593 – 602 . 
  2.  Dik  WA ,  Pike-Overzet  K ,  Weerkamp  F ,  de Ridder  D ,  de Haas  EF ,  Baert 
 MR ,  et al.  New insights on human T cell development by quantitative 
T cell receptor gene rearrangement studies and gene expression pro-
ﬁ ling .  J Exp Med  2005 ; 201 : 1715 – 23 . 
Research. 
on February 8, 2019. © 2016 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Published OnlineFirst June 28, 2016; DOI: 10.1158/2159-8290.CD-15-0675 
984 | CANCER DISCOVERYSEPTEMBER  2016 www.aacrjournals.org
Trinquand et al.RESEARCH ARTICLE
  3.  Von Boehmer  H .  Deciphering thymic development .  Front Immunol 
 2014 ; 5 : 424 . 
  4.  Gascoigne  NR ,  Palmer  E .  Signaling in thymic selection .  Curr Opin 
Immunol  2011 ; 23 : 207 – 12 . 
  5.  Klein  L ,  Kyewski  B ,  Allen  PM ,  Hogquist  KA .  Positive and negative 
selection of the T cell repertoire: what thymocytes see (and don’t see) . 
 Nat Rev Immunol  2014 ; 14 : 377 – 91 . 
  6.  Asnaﬁ   V ,  Beldjord  K ,  Boulanger  E ,  Comba  B ,  Le Tutour  P ,  Esti-
enne  MH ,  et  al.  Analysis of TCR, pT alpha, and RAG-1 in T-acute 
lymphoblastic leukemias improves understanding of early human 
T-lymphoid lineage commitment .  Blood  2003 ; 101 : 2693 – 703 . 
  7.  Asnaﬁ   V ,  Beldjord  K ,  Libura  M ,  Villarese  P ,  Millien  C ,  Ballerini  P , 
 et  al.  Age-related phenotypic and oncogenic differences in T-cell 
acute lymphoblastic leukemias may reﬂ ect thymic atrophy .  Blood 
 2004 ; 104 : 4173 – 80 . 
  8.  Ferrando  AA ,  Neuberg  DS ,  Staunton  J ,  Loh  ML ,  Huard  C ,  Rai-
mondi  SC ,  et al.  Gene expression signatures deﬁ ne novel oncogenic 
pathways in T cell acute lymphoblastic leukemia .  Cancer Cell  2002 ; 
1 : 75 – 87 . 
  9.  Homminga  I ,  Pieters  R ,  Langerak  AW ,  de Rooi  JJ ,  Stubbs  A ,  Verstegen 
 M ,  et  al.  Integrated transcript and genome analyses reveal NKX2-1 
and MEF2C as potential oncogenes in T cell acute lymphoblastic 
leukemia .  Cancer Cell  2011 ; 19 : 484 – 97 . 
 10.  Soulier  J ,  Clappier  E ,  Cayuela  JM ,  Regnault  A ,  Garcia-Peydro  M , 
 Dombret  H ,  et  al.  HOXA genes are included in genetic and bio-
logic networks deﬁ ning human acute T-cell leukemia (T-ALL) .  Blood 
 2005 ; 106 : 274 – 86 . 
 11.  Van Vlierberghe  P ,  Ferrando  A .  The molecular basis of T cell acute 
lymphoblastic leukemia .  J Clin Invest  2012 ; 122 : 3398 – 406 . 
 12.  Carron  C ,  Cormier  F ,  Janin  A ,  Lacronique  V ,  Giovannini  M ,  Daniel 
 MT ,  et al.  TEL-JAK2 transgenic mice develop T-cell leukemia .  Blood 
 2000 ; 95 : 3891 – 9 . 
 13.  Lantz  O ,  Grandjean  I ,  Matzinger  P ,  Di Santo  JP .  Gamma chain 
required for naive CD4+ T cell survival but not for antigen prolifera-
tion .  Nat Immunol  2000 ; 1 : 54 – 8 . 
 14.  Baldwin  TA ,  Hogquist  KA .  Transcriptional analysis of clonal deletion 
in vivo .  J Immunol  2007 ; 179 : 837 – 44 . 
 15.  Shi  YF ,  Bissonnette  RP ,  Parfrey  N ,  Szalay  M ,  Kubo  RT ,  Green  DR . 
 In vivo administration of monoclonal antibodies to the CD3 T cell 
receptor complex induces cell death (apoptosis) in immature thymo-
cytes .  J Immunol  1991 ; 146 : 3340 – 6 . 
 16.  Witkowski  MT ,  Cimmino  L ,  Hu  Y ,  Trimarchi  T ,  Tagoh  H ,  McKenzie 
 MD ,  et al.  Activated Notch counteracts Ikaros tumor suppression in 
mouse and human T-cell acute lymphoblastic leukemia .  Leukemia 
 2015 ; 29 : 1301 – 11 . 
 17.  Balagopalan  L ,  Coussens  NP ,  Sherman  E ,  Samelson  LE ,  Sommers  CL . 
 The LAT story: a tale of cooperativity, coordination, and choreogra-
phy .  Cold Spring Harb Perspect Biol  2010 ; 2 : a005512 . 
 18.  Huguet  F ,  Leguay  T ,  Raffoux  E ,  Thomas  X ,  Beldjord  K ,  Delabesse 
 E ,  et al.  Pediatric-inspired therapy in adults with Philadelphia chro-
mosome-negative acute lymphoblastic leukemia: the GRAALL-2003 
study .  J Clin Oncol  2009 ; 27 : 911 – 8 . 
 19.  Pui  CH ,  Evans  WE .  Treatment of acute lymphoblastic leukemia . 
 N Engl J Med  2006 ; 354 : 166 – 78 . 
 20.  Dadi  S ,  Le Noir  S ,  Payet-Bornet  D ,  Lhermitte  L ,  Zacarias-Cabeza  J , 
 Bergeron  J ,  et al.  TLX homeodomain oncogenes mediate T cell matu-
ration arrest in T-ALL via interaction with ETS1 and suppression of 
TCRalpha gene expression .  Cancer Cell  2012 ; 21 : 563 – 76 . 
 21.  Smith  SL .  Ten years of Orthoclone OKT3 (muromonab-CD3): a 
review .  J Transpl Coord  1996 ; 6 : 109 – 19 ;  quiz 20–1 . 
 22.  Martin  A ,  Tisch  RM ,  Getts  DR .  Manipulating T cell-mediated pathol-
ogy: targets and functions of monoclonal antibody immunotherapy . 
 Clin Immunol  2013 ; 148 : 136 – 47 . 
 23.  Gramatzki  M ,  Burger  R ,  Strobel  G ,  Trautmann  U ,  Bartram  CR ,  Helm 
 G ,  et al.  Therapy with OKT3 monoclonal antibody in refractory T cell 
acute lymphoblastic leukemia induces interleukin-2 responsiveness . 
 Leukemia  1995 ; 9 : 382 – 90 . 
 24.  Clappier  E ,  Gerby  B ,  Sigaux  F ,  Delord  M ,  Touzri  F ,  Hernandez  L ,  et al. 
 Clonal selection in xenografted human T cell acute lymphoblastic 
leukemia recapitulates gain of malignancy at relapse .  J Exp Med 
 2011 ; 208 : 653 – 61 . 
 25.  King  B ,  Trimarchi  T ,  Reavie  L ,  Xu  L ,  Mullenders  J ,  Ntziachristos  P , 
 et al.  The ubiquitin ligase FBXW7 modulates leukemia-initiating cell 
activity by regulating MYC stability .  Cell  2013 ; 153 : 1552 – 66 . 
 26.  Piovan  E ,  Yu  J ,  Tosello  V ,  Herranz  D ,  Ambesi-Impiombato  A ,  Da Silva 
 AC ,  et al.  Direct reversal of glucocorticoid resistance by AKT inhibi-
tion in acute lymphoblastic leukemia .  Cancer Cell  2013 ; 24 : 766 – 76 . 
 27.  Trinquand  A ,  Tanguy-Schmidt  A ,  Ben Abdelali  R ,  Lambert  J ,  Beldjord 
 K ,  Lengline  E ,  et  al.  Toward a NOTCH1/FBXW7/RAS/PTEN-based 
oncogenetic risk classiﬁ cation of adult T-cell acute lymphoblastic leu-
kemia: a Group for Research in Adult Acute Lymphoblastic Leukemia 
study .  J Clin Oncol  2013 ; 31 : 4333 – 42 . 
 28.  Schwarz  BA ,  Sambandam  A ,  Maillard  I ,  Harman  BC ,  Love  PE , 
 Bhandoola  A .  Selective thymus settling regulated by cytokine and 
chemokine receptors .  J Immunol  2007 ; 178 : 2008 – 17 . 
 29.  Yui  MA ,  Rothenberg  EV .  Developmental gene networks: a triathlon 
on the course to T cell identity .  Nat Rev Immunol  2014 ; 14 : 529 – 45 . 
 30.  Morris  GP ,  Allen  PM .  How the TCR balances sensitivity and spec-
iﬁ city for the recognition of self and pathogens .  Nat Immunol 
 2012 ; 13 : 121 – 8 . 
 31.  Hogquist  KA ,  Jameson  SC .  The self-obsession of T cells: how TCR 
signaling thresholds affect fate ‘decisions’ and effector function .  Nat 
Immunol  2014 ; 15 : 815 – 23 . 
 32.  Daniels  MA ,  Teixeiro  E ,  Gill  J ,  Hausmann  B ,  Roubaty  D ,  Holmberg  K , 
 et al.  Thymic selection threshold deﬁ ned by compartmentalization of 
Ras/MAPK signalling .  Nature  2006 ; 444 : 724 – 9 . 
 33.  Yachi  PP ,  Ampudia  J ,  Zal  T ,  Gascoigne  NR .  Altered peptide ligands 
induce delayed CD8-T cell receptor interaction–a role for CD8 in 
distinguishing antigen quality .  Immunity  2006 ; 25 : 203 – 11 . 
 34.  Prasad  A ,  Zikherman  J ,  Das  J ,  Roose  JP ,  Weiss  A ,  Chakraborty  AK . 
 Origin of the sharp boundary that discriminates positive and negative 
selection of thymocytes .  Proc Natl Acad Sci U S A  2009 ; 106 : 528 – 33 . 
 35.  Liston  A ,  Hardy  K ,  Pittelkow  Y ,  Wilson  SR ,  Makaroff  LE ,  Fahrer 
 AM ,  et  al.  Impairment of organ-speciﬁ c T cell negative selection by 
diabetes susceptibility genes: genomic analysis by mRNA proﬁ ling . 
 Genome Biol  2007 ; 8 : R12 . 
 36.  Schmitz  I ,  Clayton  LK ,  Reinherz  EL .  Gene expression analysis of thy-
mocyte selection in vivo .  Int Immunol  2003 ; 15 : 1237 – 48 . 
 37.  Davis  RE ,  Ngo  VN ,  Lenz  G ,  Tolar  P ,  Young  RM ,  Romesser  PB ,  et al. 
 Chronic active B-cell-receptor signalling in diffuse large B-cell lym-
phoma .  Nature  2010 ; 463 : 88 – 92 . 
 38.  Geng  H ,  Hurtz  C ,  Lenz  KB ,  Chen  Z ,  Baumjohann  D ,  Thompson  S , 
 et al.  Self-enforcing feedback activation between BCL6 and Pre-B cell 
receptor signaling deﬁ nes a distinct subtype of acute lymphoblastic 
leukemia .  Cancer Cell  2015 ; 27 : 409 – 25 . 
 39.  Brabb  T ,  Huseby  ES ,  Morgan  TM ,  Sant’Angelo  DB ,  Kirchner  J ,  Farr 
 AG ,  et al.  Thymic stromal organization is regulated by the speciﬁ city 
of T cell receptor/major histocompatibility complex interactions .  Eur 
J Immunol  1997 ; 27 : 136 – 46 . 
 40.  Cui  Y ,  Onozawa  M ,  Garber  HR ,  Samsel  L ,  Wang  Z ,  McCoy  JP ,  et al. 
 Thymic expression of a T cell receptor targeting a tumor associated 
antigen co-expressed in the thymus induces T-ALL .  Blood  2015 ; 125 :
 2958 – 67 . 
 41.  Kelly  JA ,  Spolski  R ,  Kovanen  PE ,  Suzuki  T ,  Bollenbacher  J ,  Pise-
Masison  CA ,  et  al.  Stat5 synergizes with T cell receptor/antigen 
stimulation in the development of lymphoblastic lymphoma .  J Exp 
Med  2003 ; 198 : 79 – 89 . 
 42.  Strzadala  L ,  Miazek  A ,  Matuszyk  J ,  Kisielow  P .  Role of thymic selec-
tion in the development of thymic lymphomas in TCR transgenic 
mice .  Int Immunol  1997 ; 9 : 127 – 38 . 
 43.  dos Santos  NR ,  Rickman  DS ,  de Reynies  A ,  Cormier  F ,  Williame  M , 
 Blanchard  C ,  et al.  Pre-TCR expression cooperates with TEL-JAK2 to 
transform immature thymocytes and induce T-cell leukemia .  Blood 
 2007 ; 109 : 3972 – 81 . 
Research. 
on February 8, 2019. © 2016 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Published OnlineFirst June 28, 2016; DOI: 10.1158/2159-8290.CD-15-0675 
 SEPTEMBER  2016CANCER DISCOVERY | 985 
TCR Activation Is Tumor Suppressive in T-cell Leukemia RESEARCH ARTICLE
 44.  Klinger  MB ,  Guilbault  B ,  Goulding  RE ,  Kay  RJ .  Deregulated expres-
sion of RasGRP1 initiates thymic lymphomagenesis independently of 
T-cell receptors .  Oncogene  2005 ; 24 : 2695 – 704 . 
 45.  Chen  Z ,  Shojaee  S ,  Buchner  M ,  Geng  H ,  Lee  JW ,  Klemm  L ,  et al.  Sig-
nalling thresholds and negative B-cell selection in acute lymphoblas-
tic leukaemia .  Nature  2015 ; 521 : 357 – 61 . 
 46.  Sanda  T ,  Tyner  JW ,  Gutierrez  A ,  Ngo  VN ,  Glover  J ,  Chang  BH ,  et al. 
 TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblas-
tic leukemia .  Cancer Discov  2013 ; 3 : 564 – 77 . 
 47.  Dail  M ,  Wong  J ,  Lawrence  J ,  O’Connor  D ,  Nakitandwe  J ,  Chen  SC , 
 et al.  Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in 
T-cell leukaemia .  Nature  2014 ; 513 : 512 – 6 . 
 48.  Kirstetter  P ,  Thomas  M ,  Dierich  A ,  Kastner  P ,  Chan  S .  Ikaros is criti-
cal for B cell differentiation and function .  Eur J Immunol  2002 ; 32 :
 720 – 30 . 
 49.  Asnaﬁ   V ,  Buzyn  A ,  Le Noir  S ,  Baleydier  F ,  Simon  A ,  Beldjord  K ,  et al. 
 NOTCH1/FBXW7 mutation identiﬁ es a large subgroup with favora-
ble outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): 
a Group for Research on Adult Acute Lymphoblastic Leukemia 
(GRAALL) study .  Blood  2009 ; 113 : 3918 – 24 . 
 50.  Bergeron  J ,  Clappier  E ,  Radford  I ,  Buzyn  A ,  Millien  C ,  Soler  G ,  et al. 
 Prognostic and oncogenic relevance of TLX1/HOX11 expression level 
in T-ALLs .  Blood  2007 ; 110 : 2324 – 30 . 
Research. 
on February 8, 2019. © 2016 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Published OnlineFirst June 28, 2016; DOI: 10.1158/2159-8290.CD-15-0675 
2016;6:972-985. Published OnlineFirst June 28, 2016.Cancer Discov 
  
Amélie Trinquand, Nuno R. dos Santos, Christine Tran Quang, et al. 
  
Leukemia
Therapeutically Targetable Tumor Suppressive Pathway in T-cell 
Triggering the TCR Developmental Checkpoint Activates a
  
Updated version
  
 10.1158/2159-8290.CD-15-0675doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 http://cancerdiscovery.aacrjournals.org/content/suppl/2016/06/28/2159-8290.CD-15-0675.DC1
Access the most recent supplemental material at:
  
  
  
  
  
Cited articles
  
 http://cancerdiscovery.aacrjournals.org/content/6/9/972.full#ref-list-1
This article cites 50 articles, 19 of which you can access for free at:
  
Citing articles
  
 http://cancerdiscovery.aacrjournals.org/content/6/9/972.full#related-urls
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.org
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
  
Permissions
  
Rightslink site. 
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerdiscovery.aacrjournals.org/content/6/9/972
To request permission to re-use all or part of this article, use this link
Research. 
on February 8, 2019. © 2016 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Published OnlineFirst June 28, 2016; DOI: 10.1158/2159-8290.CD-15-0675 
